ATM encodes a kinase that acts as a master controller of the cellular DNA damage response: it detects double-strand breaks and coordinates DNA repair, cell cycle arrest, or apoptosis through downstream targets including p53, BRCA1, and CHK2. Loss-of-function mutations in both copies of ATM cause ataxia telangiectasia, an autosomal recessive disorder characterized by neurological problems, immune deficiency, and cancer predisposition. ATM functions as a tumor suppressor: individuals with ataxia telangiectasia are prone to childhood lymphomas, leukemias, and breast cancer, while carriers of a single altered copy have increased risk of breast, pancreatic, prostate, and other cancers. Somatic ATM mutations also occur in lymphoid malignancies and solid tumors, and ATM-deficient cancers are often especially sensitive to DNA-damaging treatments.

This pathogenic classification identifies c.1039G>T as a loss-of-function ATM allele: the premature stop is predicted to trigger nonsense-mediated decay, eliminating the kinase that coordinates DNA double-strand-break repair. Carriers of such an allele carry the elevated breast, pancreatic, and prostate cancer risks described for ATM, while two altered copies would cause ataxia telangiectasia.